isradipine has been researched along with Obesity in 1 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure." | 5.07 | Obesity as a determinant for response to antihypertensive treatment. ( Gatzka, C; Rüddel, H; Schächinger, H; Schmieder, RE; Schobel, H, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schmieder, RE | 1 |
Gatzka, C | 1 |
Schächinger, H | 1 |
Schobel, H | 1 |
Rüddel, H | 1 |
1 trial available for isradipine and Obesity
Article | Year |
---|---|
Obesity as a determinant for response to antihypertensive treatment.
Topics: Blood Pressure; Body Mass Index; Double-Blind Method; Humans; Hypertension; Isradipine; Male; Metopr | 1993 |